ReviewExpert review of vaccines2014
Recent progress concerning CpG DNA and its use as a vaccine adjuvant.
Review in Expert review of vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 169 citations in OpenAlex.
- Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.Frontiers in immunology · 2023Trial
- TLR ligands as immunomodulators: mechanistic insights and therapeutic potential in infectious and inflammatory diseases.Molecular biology reports · 2026Review
- Design and mechanistic insights into ZMF59/CpG: a complementary adjuvant system boosting immunity and safety in herpes zoster vaccines.Journal of nanobiotechnology · 2026Article
- Article
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
- Microneedle delivery systems for vaccines and immunotherapy.Smart molecules : open access · 2025Review
- Gut microbiota shapes cancer immunotherapy responses.NPJ biofilms and microbiomes · 2025Review
- Article
- CpG oligodeoxynucleotide-coated chitosan nanoparticles enhance macrophage proinflammatory phenotype in vitro.Clinical and experimental immunology · 2025Article
- Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.Virology journal · 2025Article
- Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.Scientific reports · 2024Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.Scientific reports · 2024Article
- Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.Vaccines · 2024Review
- A review of immune modulators and immunotherapy in infectious diseases.Molecular and cellular biochemistry · 2024Review
- Tumor-Suppressive Cross-Linking of Anti-International journal of molecular sciences · 2024Article
- Article
- Post-Vaccination Delivery of CpG ODNs Enhances the Th2-Associated Protective Immunity of the Smallpox DNA Vaccine.Molecular biotechnology · 2024Article
- Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.International immunopharmacology · 2024Article
- Gp85 protein encapsulated by alginate-chitosan composite microspheres induced strong immunogenicity against avian leukosis virus in chicken.Frontiers in veterinary science · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.